HU190782B

HU190782B - Process for producing pharmaceutical compositions for profilacting and treating negative changes of hygienics on epithelium

Info

Publication number: HU190782B
Application number: HU811763A
Authority: HU
Inventors: Ernoe Mehesz; Ernoene Mehesz
Original assignee: Mehesz,Ernoe,Hu; Mehesz,Ernoene,Hu
Priority date: 1981-06-15
Filing date: 1981-06-15
Publication date: 1986-11-28
Also published as: JPS61221130A; HUT37565A; DE3510531A1

Abstract

The essence of the invention is, for specific multiplication of the Lactobacillus acidophilus living on epithelial tissues, where appropriate Lactobacillus bifidus, Propionibacterium and/or Corynebacterium etc, that an in vivo utilisable carbon source of 0-50% by weight, preferably one or more carbohydrates, lactic acid and/or glycerol, a nitrogen source of 0-20% by weight, preferably proteins, protein breakdown products or urea, and additional materials of 0-20% by weight, preferably salts, vitamins, growth factors, antiviral or antiphage agents and/or immunity-increasing or immunity-inhibiting agents are mixed and diluted 0-20-fold with the carrier materials customary in pharmaceutical formulation, these being added to the amount of the carbon or nitrogen source; the acidity of the mixture is adjusted by an acid, preferably by lactic acid, to a pH of 3.0-6.5; where appropriate the mixture is heat-treated between 30 and 120 DEG C and then converted by a process known per se into a therapeutic composition, preferably suppositories, tablets, ointment, chewing gum, coated tablets, injection or spray.

Description

(57) EXTRACT

The present invention relates to a method for preventing and treating negative changes in hygiene in epithelial tissues, which may be used as a specific and accelerated in vivo carrier medium for epithelial tissues.

In accordance with the invention, Lactobacillus acidophilus, which is a tissue-engineer for the specific growth of Lactobacillus bifidus, Propionibacterium, Coryne-bacteria, is useful in the treatment of epithelial tissues with 0-50% carbon source, preferably one or more carbohydrates, lactic acid and / or glycerol, 0-20% nitrogen source, protein, protein degradation products, amino acids, peptones, nucleotides, or urea, and 0-20% by weight of additive (s), preferably inorganic salt / salts, vitamin / vitamins, growth factor / factors, propolis, viral or anti-phage drugs and / or immunity mixing or inhibiting agent (s) are mixed with the carrier (s) used in the preparation of the medicament and diluted 0 to 20 times, whereby the amount of carbon or nitrogen source is included, the acidity of the mixture is adjusted to a pH of between 3.0 and 6.5 with an acid, preferably lactic acid, and the mixture if desired, heat-treated at 30-120 ° C, and then converting it into a pharmaceutical composition in a manner known per se.

. 190,782.

FIELD OF THE INVENTION The present invention relates to a method for preventing and curing a negative change in hygiene on human and animal epithelium (mucous membranes and skin), if desired, using epithelial tissue-specific and accelerated "In carrier medium" containing known drug substance (s) and living or killed microorganisms. preparation of the composition.

By hygiene we mean the current distribution of epithelial, epithelial and pathogenic microflora. The current pathology concept is wrong. Negative hygiene changes (in the vagina; fluorine, elsewhere: "fluorine-like changes") cannot be caused by any exogenous infection. With the exception of the obituary pathogens, the reason at first instance is the inadequacy of the medium of physiological microorganisms. (1). There are two major drawbacks in the theory of infection;

a) no specific prophylaxis

b) Therapy can only be solved with potentially harmful chemicals.

A number of known antimicrobial agents have been and are currently being used to influence the indicated changes. They are the most diverse; antiseptics, chemotherapeutic agents, antibiotics, etc. Due to the known potentially harmful effects of these agents, their use is only possible with the appropriate indication and caution. It is forbidden to give pregnant women without any exceptions, so their long-term use, for example in prevention, cannot be considered.

A typical example of an antimicrobial agent is the nitro derivatives commonly used in the oral, intestinal or vaginal epithelium, such as metronidazole. (5-Nitro-2-methyl- (2-hydroxyethyl) imidazole, U.S. Patent No. 2,944,061). This agent would be particularly effective against trichomonias and anaerobic bacteria. Its use focuses unilaterally on only one part of the infectious components, so the effect is only partial, but only until new infections.

In addition to therapies with antimicrobial agents, attempts have also been made to replace the physiological microorganisms, especially the lactobacilli, that are absent on the epithelium. (2) to introduce live lactic acid bacteria to acidify the vagina. According to the French patent specification, enteritis prevention is provided by the method described in U.S. Pat. French Patent Application No. 4,430 discloses a method for restoring intestinal flora using a combination of antibiotics. French patent specification.

The common aspiration of these and similar attempts is to avoid harmful antimicrobials. Their common mistake, however, is that they “forget” about the ubiquitous nature of microorganisms and try to “bring” what nature has solved.

There is a fundamental change in the treatment of mucosa in 172,501. in the Hungarian patent, since the cause of the death of physiological microorganisms is recognized in the absence of the medium. The latter, however, has the disadvantage that

Ί The effect and outcome of the generated medium is uncertain and not capturing the decisive momentum. The description does not really promise more than the production of "Döderlein-bacillus" or "Döderlein-group". "Döderlein-bacillus" .. represents various gram-positive bacteria, usually lactobacilli ... "(3)

The acid-producing ability of the different types of lactobacillus is not the same. The largest, commonly known, is the normal inhabitant of the vagina, the intestine and the oral cavity; Lactobacillus acidophilus has. (This value may be in the range of about 3.6 in vitro.) This acid concentration is not only borne by sensitive pathogens but also by the other lactobacilli species. Hygiene of epithelium is strongly influenced by the antiseptic ability of acid produced by microorganisms, especially lactic acid.

The following discoveries form the basis of the invention;

a) producing the most potent antiseptic microorganism on the epithelium,

b) we solve this task at an accelerated pace,

c) specific and complete "in-carrier"media;

d) the order of drugs is replaced by the order of nature.

We can also talk about positive and negative selectivity. The former creates the most appropriate type of biotope with complete media. The latter acts on the competitors and pulls the ground out of their feet by providing a substantial source of power that is not usable. (For example, lactose from glycogen, like xylose, etc., is not sold by the candidias.)

Media that are suitable for live cultivation of microorganisms; "Probiotic" is for.

The mode of action by which physiological microorganisms are suitable for displacing pathogens is called; "Bacilloterápiá" for.

The in vitro method that directs the synthesis capacity of microorganisms to target tasks is called biotechnology. We also produce lactic acid in live, as well as nutrient-like, acidifying industries, and ultimately create hygiene, so we recommend using the term In Carrier Biotechnology.

In addition to the feed medium of the present invention, if desired, one or more drugs may be employed, preferably antiseptic, antibiotic, trichomonocide, fungicide, antiviral and phage anti-phytic, cytostatic, immune enhancing or limiting agents, and the like. In addition to these probiotics, it is generally sufficient to administer a fraction of the usual therapeutic dose. The resulting composition can also be used directly or converted into a pharmaceutical composition suitable for external and / or internal administration.

Considering the particular sensitivity of lactobacilli (especially Lactobacillus acidophilus) to the composition of the medium, care should be taken that it can be assimilated as a source of carbon, nitrogen and so on. thinner, carrier, etc. materials are included in the components of the feed medium.

190782

It has been found that, in epithelial tissues, a pharmaceutical composition suitable for preventing and curing a negative change in hygiene, optionally containing known drug substance (s) and living or killed microorganisms, can be used as epithelial tissue-specific and accelerated in-feed medium such that Lactobacillaceae on the epithelial tissues; in particular lactobacillus acidophilus, and Lactobacillus bifidus, optionally propionibacteria, Streptococcus lactis, Streptococcus epidermidis, etc. and / or specific useful Coryebacteria, can be utilized in a 1-50% carbon source, preferably one or more carbohydrates, lactic acid, and / or glycerol, 0.5-20% by weight nitrogen source, preferably protein, protein degradation products, amino acids / acids, peptones, nucleotides, urea, and 5-40% by weight of additives / materials, preferably inorganic salts / salts, vitamins / vitamins, growth factor / Factors, virus or anti-phage agent, agents, and / or immune enhancement / inhibitory agent (s), mixed with the carrier (s) customary in the manufacture of the medicament, are diluted 0 to 20 times, where they are included in the amount of carbon or nitrogen source, acidity of the mixture with acid , preferably with a lactic acid of 3.0-6.5 pH- and adjusting the mixture, if desired, at 30 to 120 ° C, and thereafter in a manner known per se, to a pharmaceutical composition; preferably, suppository, tablet, ointment, spray, chewing gum, dragee, solution, injection, and the like. to form.

For example, the assimilable carbon source may be; one or more simple or compound sugars, sugar derivatives, starches, starches or other carbohydrates; honey, lactic acid, glycerol, alcohol, etc. too.

For example, the assimilable nitrogen source may be; protein, protein degradation product, amino acid, peptone, nucleotide, amine, peptide, popipeptide, urea, etc. One or more of these may be present in the composition.

It may also contain one or more additives, such as inorganic salts, trace elements, vitamins, growth factors, propolis, viral and anti-phage agents, and the like. stand.

It is a fast-paced medium that performs the task in less time than a simple medium. In the latter, we need to apply higher concentrations of growth factors, vitamins, substances that reduce redox potential and optimally affect pH (eg buffering agents).

Specific nutrients prepared as described above, with respect to their substance and effect, without the addition of known pharmaceutical agents, are full prophylactic and therapeutic pharmaceutical compositions. The point here is the destruction of microorganisms, but this effect is indirectly, biologically. The benefits of this effect can be summarized as follows.

After the use of the preparation, useful physiological microorganisms (especially the members of the Lactobacillaceae genus) appear and multiply, and disappear in parallel with other or pathogenic microorganisms.

Clinical symptoms; redness, pain, itching, etc. disappear after hours of application. The composition according to the invention can be used in the following areas:

correction of negative hygiene changes in body cavities. (Oral cavity, throat, intestines, vagina, skin, etc.).

¹⁰ Digestive disorders; diarrhea, constipation, bloating, etc. treating the intestinal flora, displacing putrificants from the small intestine. (Realization of 'acidophilus milk' in loco.) Dentistry; of parodontosis and caries pre venciója ^15; partly to correct the negative effects of the current flora of the mouth, but also to the negative effects of modern nutrition habits (kitchen appliances, beet sugar, yeasts, etc.).

Caring for women with vagino hygiene, extending maternity ²⁰ asepsis (Semmelweis) in the form of functional antisepsis for all ages. It can be especially useful for pregnant women, children and the elderly. (3)

From the gut flora of the elderly or the serious patients, there are as many as 25 vaginal secretions of lactobacilli as elderly women. The bacilli of the Muchnykov yogurt do not live in the intestine, but L.acidophilus and L.bifidus are also normal intestinal colonies. Even in the intestines of adults, the presence of lactobacillus populations would be normal with infants. This would ensure that pathogens representing a wide range of harm are excluded from the intestines. All this is solved by completing the medium of the invention.

Veterinary Medicine.

Breastfeeding mammals; pig, calf, foal, dog, etc. 90% of its intestinal flora consists of lactobacilli as well as the human infant. Early episodes of premature death, the lactobacillus flora, occur in 40 today with antibiotic treatment of suckling mammals. We can substitute all these with probiotics. summary; suitable media means that the microorganisms can also be grown in vivo. 45 According to the Natural Law of Milk Model (Méhész E.), lactobacilli are able to displace other pathogenic flora by fermentation. Probiotics also prove this in vivo.

The depreciation of the medium is a negative change in the hygiene of the initial element 50, which can be reversible by completing the medium. The code of the milk model is not only an option, but also a statutory requirement. Where we do not find the dominance of the latter in the ordinary biotope of the lactobacilli, we have to hope. With the live production of fermentation, biotechnology can become a method of medicine.

Literature

1. A. Döderlein: Das Scheidensecret und Seine Bedeutung für das Puerperalfieber, Eduard Besold,

Leipzig, 1892.

2. Loeser A .; Dér Fluor, The Entstehung und Eine Neue Season Therapie mittels des Bakteriumpreparates “Basil”. Zbl. Gynák. 1920, 44, 417.

3. ₅ 3. Béla Lányi: Epidemiological and Clinical Bacteria3

190 782 ί

I!

National Institute of Public Health, 1980. Budapest.

4. Méhész E .: Vaginale Antisepsis Durch Locale Vermehrung von Laktobacilli-Jubilee-Congress IF Semmelweis und GA Michaelis, Budapest, 1983. - Abstr. 32nd

The following examples illustrate the process of the invention:

MgCO 3 0.01 to 1.0 g of folic acid 0.02 to 0.05 micrograms of hydroxocobalamin 1.0 to 3.0 micrograms are homogenized with cocoa butter or polyoxethenum-1540, the acidity of the mixture is adjusted to pH 4.0 and After proper shaking, 3 g of suppositories are prepared and mixed with 44% glycerol in water and used as an ointment.

Example I.

laktacid 1.0-6.0 g glucose 1, <M, 0 g urea 0.1-2.0 g and the desired Vitamin B Mixture in; 0.5-5.0 g potassium dihydrogen phosphate 0.1-1.5 g Tween-80 0.5-4.0 g agar-agar powder 0.1-5.0 g tripkazin Example 2 1.0-4.0 g saccharose 0.2-2.0 g glucose 0.1-2.0 g lactose 0.1 - 1.0 g lactic acid 0.5-4.0 g Vitamin B Mixture 1.0-3.0 g Cooking 1.0-3.0 g folic Acid 0.03-0.20 g

In both examples, the listed components are homogenized and the powder mixture or granulate is added without carrier, or injected.

filled into a soluble capsule. Example 3 p-aminobenzoic acid ethyl- ester 0.5-5.0 g lactic acid 1.5-3.0 g Na acetate 1.0-4.0 g glycerol 2.0-5.0 g lactose 5.0-20 g thymidine 0.01 to 0.05 micrograms Vitamin B-12 0.01-0.1 µg.

Example 5

peptone 1.0-3.0 g acid-digested casein 3.0-8.0 g ammonium chloride 1.0-3.0 g B-vitamin mix 3.0-15.0 g p-Amino-benzoic acid ethyl ester 2.0-4.0 g folic Acid 10.0-15.0 micrograms lactose 6.0-20.0 g xylose 1.0-5.0 g oleic acid 1.0-5.0 g Tween-80 1.0-5.0 g glycerol 2.0-15.0 g ascorbic acid 5.0-15.0 g lactic acid 2.0-8.0 g Sodium acetate 2.0-8.0 g calcium lactate 1.0-5.0 g Vitamin B-12 1.0-3.0 micrograms hydroxocobalamin 1.0-3.0 micrograms MnCl ₂ 0.01-0.03 mg and if desired: Sodium phosphate 5.0-15.0 g agar-agar powder 5.0-15.0 g thymine 0.01 to 0.03 micrograms glycine 0.1-0.3 mg Cooking 5.0-15.0 g eating tomato juice 5.0-20.0 g gelatine 10-20.0 g

The components were homogenized with 100 g of cocoa butter, the acidity of the mixture was adjusted to pH 4.0, and after supposing shaking, 3 g of suppositories were prepared. If desired; after homogenization of the mixture, by spraying with CO ₂ propellant in a known manner in a known manner.

The mixture is homogenized, its acidity adjusted to pH 4.0, preferably with lactic acid and citric acid, and 400 known half-gram tablets are prepared with known carriers and method, which are coated with intestinal solvent coating and mixed with chewing gum base to prepare 400 chewing gum.

Example 4

peptone 0.5-4.0 g ammonium chloride 1.0-3.0 g p-amino-benzoate 1.0-6.0 g 55 lactose 5.0-15.0 g xylose 0.5-3.0 g xylitol 0.1-2.0 g oleic acid 0.5-5.0 g glycerol 2.0-5.0 g 60 lactic acid 1.0-4.0 g Sodium acetate 2.0-6.0 g calcium lactate 0.1-1.5 g and desired MnCl ₂ in; 0.01-0.02 g 65

Example 6 Acid-digested casein 1.0-5.0 g tryptically digested casein 1.0-7.0 g ammonium chloride 1.0-5.0 g p-aminobenzoic acid ethyl ester magnesium carbonate vitamin B mixture glucose lactose ascorbic acid folic acid glycerol vitamin B 12 sodium phosphate oleic acid linseed oil

1.0-7.0 g 3.0-5.0 g 5.0-7.0 g 8.0-15.0 g 15.0-25.0 g 5.0-10.0 g

1.0-2.0 micrograms 8.0-10.0 g

300.0-900.0 micrograms 10.0-30.0 g 5.0-10.0 g 1.0-1.0 g

190 782 sunflower oil and, if desired: sodium acetate sodium fluoride MnCl ₂ agar-agar powder

Tween-80 Salt Honey Wax Propolis Iron (II) Sulfate

Vitamin A

Vitamin D 2

Vitamin D 3

3.0-8.0 g

3.0-8.0 g of 0.001-0.003 g 0.001-0.003 mg 3.0-5.0 g 1.0-5.0 g 1.0-5.0 g 2.0-9.0 g 1, 0-2.0 g 1.0-2.0 g 1.0-3.0 g 50 thousand NE 200 thousand NE 800 thousand NE of the listed parts are homogenized, the acidity of the mixture is adjusted to pH 4.0 with lactic acid, then 200 g of stearin or potassium, etc. we make soap in a known manner.

The mixture was homogenized, supplemented with distilled water to 100 g, acidity adjusted to pH 7.0 and filled into 2-5 ml vials as usual. Usually sterilized.

Example 2.0-5.0 g 1.0-6.0 g

1.0-7.0 g

0.3-0.10 micrograms 1.0-3.0 g

0.2-3.0 g of 0.01-0.2 g of 1.0-10.0 mg ml

Example 7

acid-digested casein 3.0-5.0 g tryptic digestion zein 3.0-5.0 g gelatine 1.0-5.0 g lactose 2.0-15.0 g xylose 1.0-5.0 g xylitol 1.0-2.0 g Sodium fluoride 0.001-0.03 g B-vitamin mix 7.0-15.0 g aszkorbiifsav 3.0-6.0 g folic Acid 3.0-6.0 micrograms Tween-80 2.0-5.0 g Vitamin B 12 100-1000 micrograms Sodium acetate 5.0-7.0 g para-aminobenzoic acid ethyl ester 4.0-7.0 g glycerol 6.0-12.0 g and as required; thymidine 1.0-1.5 micrograms glycine 5.0-7.0 micrograms Cooking 5.0-12.0 g MnCI ₂ 0.001-0.005 micrograms Vitamin A 200 thousand NE Vitamin D 2 500 thousand NE Vitamin D 3 800 thousand NE ferrous sulfate 1.0-2.0 g eating tomato juice 5.0-20.0 g cod liver oil 2.0-5.0 g

The above mixture is homogenized, mixed with one hundred grams of conventional toothpaste base, acidity of the mixture is adjusted to pH 4.0 with lactic acid and citric acid and added to a tooth cube.

lactic acid glycerol p-amino-benzoic acid ethyl ester folic acid

Vitamin B Mixture And As Required: Propolis Podophylline Estradiol Propionate Lactobacillus, Preferably Lactobacillus Acidophilus Suspension (2 10 ° Cell / m)

The listed components were homogenized with 100 g of polyethylene, the acidity of the mixture was adjusted to pH 4.0, and suppositories were prepared by shaking with a weight of 3 g.

We investigated the effect of the suppositories, for prevention, in 160 women aged 15-50, with a cone of a cone per day. After 1-7 days of treatment, lactobacilli, predominantly Lactobacillus acidophilus, was present in the vagina in 70% of the treated patients. For cure, 200 women aged 12 to 50 years were treated with one vaginal per day. In 50% of patients, 8-14 days later, a practical color culture of lactobacilli was detected in the vagina. At the same time, the negative change in vaginal hygiene, the fluorescent disease, was also an objective and subjective symptom.

Example 10

tryptic digestion casein 1.0-2.5 g Vitamin B Mixture 2.0-7.0 g lactose 2.0-9.0 g xylose l 0-3,0g xylitol 1.0-2.0 g Sodium acetate 1.0-5.0 g ascorbic acid 0.5-3.0 g and if desired: sulfathiourea 500.0-1000.0 mg metronidazole 500.0-1000.0 mg oxytetracyklinum 500.0-1000.0 mg hexachlorophene 1.0-3.0 g

Example 8

tripkazin 1.0: 0 g saccharose 0.1-20.0 g glucose 1.04.0 g lactose 1.04.0 g Vitamin B Mixture 1.0-3.0 g lactic acid 0.1-2.0 g Cooking 0.5-3.0 g folic Acid 0.3 to 0.20

The mixture is heat-treated at 30-110 ° C, then carbon dioxide or other suitable propellant, and the usual excipients, are dispensed in 100 g spray form. The mixture was adjusted to pH 4.0 with lactic acid. Instead of spray form, the mixture is filled with glass with suitable diluent, body cavities; mouth, bowel, vagina, etc. it is also used as a flushing liquid. The pH of the rinse form may be from 3.0 to 5.0.

The “Vitamin B Mixture” is the same as that of the Kőbánya Pharmaceutical Factory POLYBÉ, the composition of which is the “Guide to Ordering Medicinal Products”. (published by the National Institute of Pharmacy, 1980).

-5190,782

Claims

1.0-4.0 g

2.0-5.0 g

Na-acetate glycerol

1. Procedure for epithelial tissue, hygiene becomes negative

For the prevention and cure of lactose intakes of 5.0-20.0 g,

0.01 to 0.05 micrograms of thymidine, which is a member of the lactobaciilaceae germ, living in the epithelium, especially Lactobacillus acidophi

0.01-0.1 micro lus, Lactobacillus bifidus, and Streptococcus

gram

Vitamin B 12 lactis, Streptococcus epidermidis, Propioni

4. Specificity of 0.5-4.0 g of peptone bacteria and / or Corynebacteria

1.0-3.0 g of ammonium chloride for inoculation and accelerated growth

1.0-6.0 g of p-aminobenzoic acid for the preparation of a compound of the type of culture medium,

ester

- partially digested protein preparations, e.g.

5.0-15.0 g lactose partially digested milk proteins, preferably lactic acid,

0.5-3.0 g xylose tryptically digested casein, liver or meat proteins,

0.1 to 2.0 g of xylitol are preferably peptone, yeast and liver extract;

0.5-5.0 g of oleic acid

amino acids (preferably glycine, p-amino)

2.0-5.0 g of glycerol zoic acid) and their esters;

1.0-4.0 g of lactic acid

- urea;

2.0-6.0 g

Na-acetate,

inorganic ammonium salts (preferably ammonia)

Calcium lactate (0.1-1.5 g);

and if desired

- mono- and disaccharides (preferably glucose,

0.01-0.02 g

MnCl _z -t lactose, sucrose, xylose) or derivatives thereof;

0.01-1.0 g

MgCOj at

- organic acids (preferably lactic acid, oleic acid, as

0.02-0.05 microbic acid, acetic acid) and their salts;

grams of folic acid

purine and pyrimidine bases, DNA;

1.0-3.0 micrograms of hydroxocobalamin

- glycerol;

5. 1.0-3.0 g of peptone

- vegetable and fruit salads,

3.0-8.0 g of acid-digested cascade or killed lactobacillus suspensions as

int major nutrient components and, if desired, major

1.0 to 3.0 g of max. 40% by weight30

3.0-15.0 g

Vitamin B Mixture is an additive used in the pharmaceutical industry

2.0-4.0 g of p-aminobenzoic acid ethyl, preferably

ester

- vitamins;

10.0-15 micrograms of folic acid

- buffering agents (preferably phosphate salts);

6.0-20.0 g of lactose

emulsifiers (preferably Tween) 35

1.0-5.0 g xylose strands);

1.0-5.0 g of oleic acid

- fabrics (preferably agar-agar);

1.0-5.0 g

Tween-80

- inorganic salts;

2.0-15.0 g of glycerol

- enzymes;

5.0-15.0 g of ascorbic acid

- propolis, honey

2.0-8.0 g of lactic acid

ointment base materials (preferably cocoa butter, po

2.0-8.0 g

Na-acetate lyoxetene, zinc paste, eucerin)

1.0 to 5.0 g of calcium lactate

- use propellants, preferably carbon dioxide

1.0-3.0 micrograms

Vitamin 12-12, characterized in that

1.0-3.0 micrograms of hydroxyobalamin

1. 1.0-6.0 g of lactic acid and if desired

1.0-4.0 g of glucose

5.0-15.0 g of sodium phosphate

0.1 to 2.0 g of urea,

5.0-15.0 g of agar-agar powder and if desired;

0.01 to 0.03 micro

0.5-5.0 g

Vitamin B Mixture

grams of thymine

0.1-1.5 g of potassium dihydrogen 50

0.01 to 0.3 milligrams of glycine

phosphate

5.0-15.0 g of sodium salt

0.5-4.0 g

Tween-80,

5.0 to 20.0 g of food tomato 0.1 to 5.1 g of agar-agar powder

It raises,

2. 1.0-4.0 g of tricasin

10.0-20.0 g of gelatin

0.2-2.0 g of sucrose

6. 1.0 to 5.0 g of acid-digested caseo-0.1 to 2.0 g of glucose

int

1.0-4.0 g of lactose

1.0-7.0 g of tryptic digestion

0.5-4.0 g of lactic acid and the desired case

casein

in,

1.0-5.0 g of ammonium chloride

1.0-3.0 g

B-vitamin mix

1.0-7.0 g of p-aminobenzoic acid ethyl 1.0-3.0 g

NaCl

ester

0.03-0.20 g of folic acid

3.0-5.0 g of magnesium carbonate

3. 0.5-5.0 g of p-aminobenzoic acid ethyl

5.0-7.0 g

B-vitamin mix

ester

8.0-15.0 g of glucose

1.5-3.0 g of lactic acid

15.0-25.0 g of lactose

-61. 190,782 2

5.0-10.0 g of ascorbic acid

6.0-12.0 g of glycerol.

1.0-2.0 microfluids

and grams if necessary

1.0-1.5 micrograms thymidine

8.0-10.0 g of glycerol

5.0-7.0 micrograms of glycine

300.0-900.0 microB Vitamin 12

5.0 to 12.0 g of salt per gram

0.001-0.005 micro10.0-30.0 g of sodium phosphate

gram

T-MnCIj

5.0-10.0 g of oleic acid

200 thousand NE

The vitamin

1.0-2.0 g of linseed oil

500 thousand NE

Vitamin D-2

3.0-8.0 g of sunflower oil

800 thousand NE

Vitamin D-3 and if desired

1.0-2.0 g of ferrous sulfate

3.0-8.0 g of sodium acetate

5.0-20.0 g of eating tomato juice

0.001-0.003 g of sodium fluoride

2.0-5.0 g of cod liver oil

0.001-0.003 mill

8. 1.0-4.0 g of trypsin per gram

MnCl ₂

0.1-20.0 g of sucrose

3.0-5.0 g of agar-agar powder

1.0-4.0 g of glucose

1.0-5.0 g

Tween-80

1.0-3.0 g of lactose

1.0 to 5.0 g of sodium salt

1.1-3.0 g

Vitamin B Mixture

2.0-9.0 g of honey

0.1-2.0 g of lactic acid

1.0-2.0 g of wax

0.5 to 3.0 g of sodium salt

1.0-2.0 g of propolis

0.3-0.20 micrograms of folic acid

1.0-3.0 g of ferrous sulfate

9. 2.0-5.0 g lactic acid per thousand NE

Vitamin A

1.0-6.0 g of glycerol

200 thousand NE

Vitamin D 2

1.0-7.0 g of p-aminobenzoic acid ethyl 800,000 NE

Vitamin D 3

ester

7. 3.0 to 5.0 g of acid-digested goat

0.3-0.10 micrograms of folic acid

int

1.0-3.0 g

B-vitamin mix

3.0-5.0 g of tryptic digestion

and as required;

casein

0.2 to 3.0 g of propolis

1.0 to 5.0 g of gelatin

0.001-0.2 g podophylline

2.0-15.0 g of lactose

1.0-10.0 mg of estradiol propionate

1.0-5.0 g of xylose

ml Lactobacillus, preferably Lactobacillus eye 1.0-2.0 g xylitol

dophilus suspension (2 x 10 ⁶ cells / ml) combined with 0.001-0.03 g of sodium fluoride

the usual carrier for pharmaceutical preparation is 7.0-15.0 g

Vitamin B mixture with gels, propellant, diluents; texture adjusting nut3.0-6.0 g ascorbic acid

diluted with 0-20 times the pH of the mixture

3.0 to 6.0 micrograms of folic acid

with an acid, preferably lactic acid, between 3.0 and 7.0.

2.0-5.0 g

Tween-80

and, if desired, a temperature of from 30 to 120 ° C to 1000 microns

heat treatment and therapeutically.

gram

Vitamin B12 is preferably powder, solution, suppository, tablet, chewing gum, 5.0-7.0 g sodium acetate

females, dragee, spray, injection, soap, toothpaste

4.0-7.0 g of ethyl ester of p-aminobenzoic acid

to form.

Without drawing